Skip to content
OpenCapital
Get started

Rhythm Pharmaceuticals, Inc. RYTM Single reportable segment — Commercial & medical affairs

Similar metrics at other companies

Mirum Pharmaceuticals, Inc. logo
MIRMReportable Segment — Commercialization and Medical Affairs expenses (excluding stock-based compensation)
$44.22M+23.6%
Incyte logo
INCYReportable Segment — Sales and marketing
$259.56M+0.7%
Guardant Health logo
GHReportable Segment — Sales and marketing expense
$154.43M+64.1%
Amgen logo
AMGNReportable Segment — Sales and marketing
$1.13B+6.4%
Eli Lilly logo
LLYReportable Segment — Marketing, selling, and administrative
$2.93B+18.9%
PayPal Holdings, Inc. logo
PYPLReportable Segment — Sales and marketing
$518M+6.1%

Other financials

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%
CapEx$238.3K—
Free cash flow-$29.2M-2.4%

Valuation

See full
Market cap$6.64B+77.3%
Enterprise value$6.69B+78.4%
P/S30.6×+3.2×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp
FCF margin-61.5%-14.1pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept rytm:CommercialAndMedicalExpenses.

The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rhythm Pharmaceuticals, Inc.'s single reportable segment — commercial & medical affairs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rhythm Pharmaceuticals, Inc.'s single reportable segment — commercial & medical affairs?
Rhythm Pharmaceuticals, Inc. (RYTM) reported single reportable segment — commercial & medical affairs of $20.26M in Q1 2026.
How has Rhythm Pharmaceuticals, Inc.'s single reportable segment — commercial & medical affairs changed year-over-year?
Rhythm Pharmaceuticals, Inc.'s single reportable segment — commercial & medical affairs increased by 52.9% year-over-year, from $13.25M to $20.26M.
What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s single reportable segment — commercial & medical affairs?
Over 3 years (2022 to 2025), Rhythm Pharmaceuticals, Inc.'s single reportable segment — commercial & medical affairs has grown at a 17.1% compound annual growth rate (CAGR), from $41.76M to $66.96M.
What does single reportable segment — commercial & medical affairs mean?
This metric measures the expenditures related to marketing, sales force support, and medical education initiatives for the company's commercialized products. It reflects the investment in building brand awareness, physician education, and patient access programs. Tracking this helps evaluate the cost-effectiveness of the company's go-to-market strategy.